Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

163. Cytochrome P450 gene test to establish the correct warfarin dose in patients requiring oral anti-coagulant therapy

Cytochrome P450 gene test to establish the correct warfarin dose in patients requiring oral anti-coagulant therapy Cytochrome P450 gene test to establish the correct warfarin dose in patients requiring oral anti-coagulant therapy Cytochrome P450 gene test to establish the correct warfarin dose in patients requiring oral anti-coagulant therapy Mundy L, Hiller JE Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Mundy L, Hiller JE. Cytochrome P450 gene test to establish the correct warfarin dose in patients requiring oral anti-coagulant therapy. Adelaide: Adelaide Health Technology Assessment (AHTA). Horizon Scanning Prioritising Summary Volume 26. 2010 Authors' conclusions Polymerase chain reaction is an accurate means of identifying genetic mutations. All techniques discussed in this summary use PCR and other molecular techniques

Health Technology Assessment (HTA) Database.2010

164. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy

Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R, Virdi G (...) , Abrams D, Sporton S, Dhinoja M, Earley M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the clinical and economic impact of warfarin versus heparin for patients undergoing catheter ablation for typical atrial

NHS Economic Evaluation Database.2010

165. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of genetic testing to adjust the warfarin dose, using a model based on the international normalised ratio, for patients with atrial fibrillation who had just started long-term warfarin therapy. The authors concluded that warfarin pharmacogenomic testing provided some clinical benefit, but with significant

NHS Economic Evaluation Database.2010

166. Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention

Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention – TheNNTTheNNT Oral anticoagulants versus antiplatelet agents in non-valvular atrial fibrillation for stroke prevention (and no prior stroke) 60 for prevented stroke In Summary, for those who took warfarin instead of aspirin (for 1.9 years): Benefits in NNT 98.8% saw no benefit 1.6% were helped by preventing 1 stroke 0.3% were helped by avoiding a systemic embolism 1 (...) . The overall risk of stroke ranges from 2.5% to 4% per year. Both anti-platelet agents and oral anticoagulants reduce this risk, but both also increase the risk of hemorrhagic stroke and other bleeding. The review compared anti-platelet agents to anticoagulants in patients with atrial fibrillation but no history of stroke or transient ischemic attack. Eight randomized trials with 9598 subjects were included, with most examining warfarin versus aspirin (75 to 325 mg/day). The target INR range for subjects

theNNT2010

167. Warfarin for Atrial Fibrillation Stroke Prevention

Warfarin for Atrial Fibrillation Stroke Prevention Warfarin for Atrial Fibrillation Stroke Prevention – TheNNTTheNNT Oral anticoagulants in non-valvular atrial fibrillation for primary stroke prevention (no prior stroke) 25 for prevented stroke In Summary, for those who took the warfarin (for 1.5 years): Benefits in NNT 96% saw no benefit 4% were helped by preventing 1 stroke 2.4% were helped by avoiding death 1 in 25 were helped (preventing stroke ) 1 in 42 were helped (preventing death from (...) factor for strokes. The overall risk ranges from 2.5% to 4% per year. Oral anticoagulants (OAC) reduce this risk, but also increase the risk of hemorrhagic stroke and major bleeding. The review compared warfarin with placebo for prevention of stroke in patients with atrial fibrillation but no history of strokes (or transient ischemic attacks). Five high quality trials with 2313 participant were included, most examining warfarin versus placebo. The warfarin group achieved a mean INR between 2.0

theNNT2010

168. Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction

Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction Haq SA, Heitner JF, Sacchi TJ, Brener SJ CRD summary This review concluded that long-term oral anticoagulation with warfarin did not reduce mortality or reinfarction after myocardial infarction, although (...) there was a significantly higher rate of bleeding balanced by a reduction in the rate of stroke. These conclusions follow from the presented evidence but, given limitations in the conduct and reporting of the review, they may not be reliable. Authors' objectives To evaluate the risk and benefit of long-term oral anticoagulation with warfarin after myocardial infarction. Searching PubMed and Ovid SR were searched for relevant evidence published in any language. Search terms were reported, but search dates were

DARE.2010

169. Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients With Atrial Fibrillation: A Systematic Review

Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients With Atrial Fibrillation: A Systematic Review "Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients " by Kristi M. Crowell < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background (...) : Atrial fibrillation (AF) is the most common dysrhythmia among elderly patients. A co-morbidity associated with this disease process is embolic stroke. In an effort to reduce the potential morbidity and mortality associated with stroke, patients are often placed on the anticoagulant warfarin. While warfarin has been statistically proven to reduce the rate of embolic stroke in patients with AF, it potentiates increased risk of bleeding. The elderly population has an elevated level of AF and increased risk for fall

Pacific University EBM Capstone Project2010

170. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. 20801496 2010 09 20 2010 09 30 2016 06 22 1474-547X 376 9745 2010 Sep 18 Lancet (London, England) Lancet Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (...) . 975-83 10.1016/S0140-6736(10)61194-4 Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2·0-3·0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced both stroke and haemorrhage. We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population. In the RE-LY trial

Lancet2010

171. The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. BACKGROUND: Guidelines recommend warfarin use in patients with atrial fibrillation solely on the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on ischemic stroke rates observed in older trials and do not explicitly account for increased risk for hemorrhage. OBJECTIVE: To quantify the net clinical benefit of warfarin therapy in a cohort of patients with atrial fibrillation (...) . DESIGN: Mixed retrospective and prospective cohort study of patients with atrial fibrillation between 1996 and 2003. SETTING: An integrated health care delivery system. PATIENTS: 13 559 adults with nonvalvular atrial fibrillation. MEASUREMENTS: Warfarin exposure, patient characteristics, CHADS(2) score (1 point for each of congestive heart failure, hypertension, age, and diabetes and 2 points for stroke), and outcome events were ascertained from health plan records and databases. Net clinical benefit

Annals of Internal Medicine2009 Full Text: Link to full Text with Trip Pro

172. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. The U.S. Food and Drug Administration modified warfarin labeling in 2007 to suggest, but not mandate, pharmacogenetic testing. Genetic analysis is now commercially available. However, results predict only one third of all dosing variation, the value of testing in reducing bleeding and thrombosis rates remains unproved, and cost-effectiveness is not established. Careful consideration of clinical factors (...) that influence dosing, conscientious prothrombin time monitoring, and sage dosage adjustment remain paramount in warfarin management. Further study is required before routine warfarin pharmacogenetic testing can be recommended.

Annals of Internal Medicine2009

173. Thrombomodulin as a marker for bleeding complications during warfarin treatment

Thrombomodulin as a marker for bleeding complications during warfarin treatment 19597070 2009 07 14 2009 08 06 2015 11 19 1538-3679 169 13 2009 Jul 13 Archives of internal medicine Arch. Intern. Med. Thrombomodulin as a marker for bleeding complications during warfarin treatment. 1210-5 10.1001/archinternmed.2009.170 The major adverse effect of warfarin treatment is hemorrhage. Several risk factors for bleeding complications are also risk factors for thromboembolic events, making the clinical (...) decision to initiate or withhold anticoagulant treatment difficult. Specific markers that solely identify patients at high risk of bleeding would have great clinical impact. This study aimed to test if thrombomodulin (TM) concentrations were associated with bleeding complications, cardiovascular events, or mortality in long-term anticoagulant-treated patients. In a longitudinal cohort study we followed up 719 patients receiving warfarin treatment for a mean duration of 4.2 years. All bleeding

EvidenceUpdates2009

174. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial 19289640 2009 03 31 2009 04 24 2013 11 21 1524-4539 119 12 2009 Mar 31 Circulation Circulation Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 1616-24 10.1161/CIRCULATIONAHA.108.801753 Chronic heart (...) failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily

EvidenceUpdates2009

175. Estimation of the warfarin dose with clinical and pharmacogenetic data.

Estimation of the warfarin dose with clinical and pharmacogenetic data. BACKGROUND: Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large population. We developed and used an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from a broad (...) population base. METHODS: Clinical and genetic data from 4043 patients were used to create a dose algorithm that was based on clinical variables only and an algorithm in which genetic information was added to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant

NEJM2009 Full Text: Link to full Text with Trip Pro

176. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. BACKGROUND: Variants in genes involved in warfarin metabolism and sensitivity affect individual warfarin requirements and the risk for bleeding. Testing for these variant alleles might allow more personalized dosing of warfarin during the induction phase. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb (...) , Princeton, New Jersey), suggesting that clinicians consider genetic testing before initiating therapy. OBJECTIVE: To examine the cost-effectiveness of genotype-guided dosing versus standard induction of warfarin therapy for patients with nonvalvular atrial fibrillation. DESIGN: Markov state transition decision model. DATA SOURCES: MEDLINE searches and bibliographies from relevant articles of literature published in English. TARGET POPULATION: Outpatients or inpatients requiring initiation of warfarin

Annals of Internal Medicine2009

177. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Eckman MH, Rosand J, Greenberg SM, Gage BF Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of a genotype-guided dose titration strategy compared with the standard induction dosage of warfarin for patients with non-valvular atrial fibrillation. The authors concluded that genotype-guided warfarin dosage was unlikely

NHS Economic Evaluation Database.2009

178. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of warfarin treatment in patients with atrial fibrillation, who were at moderate-to-high risk of ischaemic stroke, and considered various scenarios for treatment adherence and discontinuation. The cost-effectiveness of warfarin and its beneficial effect deteriorated with poorer

NHS Economic Evaluation Database.2009

179. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation Patrick AR, Avorn J, Choudhry NK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the circumstances in which genotyping before warfarin initiation could be cost-effective for patients with atrial fibrillation. Genotyping was cost-effective only if it reduced the out-of-range international normalised ratios by more than five to nine percentage points. There was uncertainty surrounding the effectiveness of genotyping and its

NHS Economic Evaluation Database.2009

180. Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarinOral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal (...) after receiving warfarin Article Text Therapeutics Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin Statistics from Altmetric.com No Altmetric data available for this article. STUDY DESIGN Design: randomised, placebo-controlled trial. ClinicalTrials.gov NCT00143715. Allocation: concealed.* Blinding: blinded (patients, clinicians

Evidence-Based Medicine (Requires free registration)2009